Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Lai

Psychiatry San Francisco, CA Medical Doctor

NPI 1215054689 CMS profile 54342

2159 Union St, Dr. Alan Lai, San Francisco, CA 94123

Open in the dashboard

General payments

$4,025

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Lai of San Francisco, CA is reported in the CMS Open Payments database as having received $4,025 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $173 5
2024 General $269 8
2023 General $348 14
2022 General $776 29
2021 General $944 32
2020 General $684 27
2019 General $831 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Lai
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Alan Lai were reported at $173. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Alan Lai Psychiatry median Middle half National median
2019 $831 $184 $59–$605 $163
2020 $684 $119 $36–$372 $114
2021 $944 $143 $43–$576 $132
2022 $776 $153 $50–$590 $149
2023 $348 $170 $56–$651 $160
2024 $269 $179 $57–$673 $164
2025 $173 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,362 49 payments
  2. Lundbeck LLC $863 39 payments
  3. Sunovion Pharmaceuticals Inc. $761 35 payments
  4. Axsome Therapeutics, Inc. $472 14 payments
  5. ITI, Inc. $340 15 payments
  6. Shire North American Group Inc $178 7 payments
  7. Otsuka America Pharmaceutical, Inc. $25 1 payment
  8. Boston Scientific Corporation $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,025 161 payments
Products named General payments · program years 2019–2025
  1. TRINTELLIX Neuroscience $1,339 45 payments
  2. LATUDA $761 35 payments
  3. REXULTI Psychiatry $705 29 payments
  4. Auvelity $472 14 payments
  5. CAPLYTA $340 15 payments
  6. Trintellix Central Nervous System (CNS) $177 10 payments
  7. BRINTELLIX $158 10 payments
  8. REXULTI Psychiatry $25 1 payment
  9. VYVANSE $25 1 payment
  10. TRUSELECT $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

196

Median for Psychiatry & Neurology: 100

Drug cost

$13,418

Median for Psychiatry & Neurology: $2,986

Branded share of claims

47.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 15 $10,946
Venlafaxine Hcl Er Venlafaxine Hcl Brand 37 $779
Bupropion Xl Bupropion Hcl Brand 18 $602
Escitalopram Oxalate Generic 27 $390
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 23 $343
Lorazepam Generic 22 $114
Duloxetine Hcl Generic 12 $80
Mirtazapine Generic 16 $75
Topiramate Generic 14 $53
Alprazolam Generic 12 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $269
$269 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record